文献速递甲状腺疾病

放射性碘再分化治疗在既往碘难治性分化型甲状腺癌中的临床结局

Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
PubMed 文献 · Thyroid · 2023-12-12

本研究为梅奥诊所33例RECIST进展的转移性碘难治性分化型甲状腺癌患者的回顾性病例系列,患者接受MEK、RET或ALK抑制剂单药或BRAF-MEK联合抑制剂4周后行再分化治疗。57.6%患者恢复放射性碘摄取,RAS突变肿瘤全部再分化而BRAF突变者为38.9%;再分化亚组在高剂量131I治疗后6个月肿瘤额外缩小中位20%。两组在无进展生存、启动系统治疗时间和启动任何额外治疗时间上无统计学显著差异。

要点

  • 33例碘难治性分化型甲状腺癌患者中57.6%经再分化治疗恢复放射性碘摄取。
  • RAS突变肿瘤全部再分化,BRAF突变肿瘤仅38.9%再分化。
  • 再分化亚组高剂量131I治疗后6个月肿瘤额外缩小中位20%。

核心结论

  • 再分化治疗有潜力在部分碘难治性分化型甲状腺癌患者中恢复放射性碘亲和力并在131I治疗后诱导RECIST缓解,尤其是RAS驱动的「滤泡」表型患者。
  • 在甲状腺乳头状癌患者中,再分化亚组与未再分化亚组之间所评估的临床结局均无统计学显著差异。
  • 需要进一步研究以更好地描述再分化治疗后高剂量放射性碘的长期生存和/或安全性结局,特别是其是否可能与组织学间变性转化相关。

研究设计与样本

  • 本研究为回顾性病例系列,纳入2017年至2022年在梅奥诊所(明尼苏达州罗切斯特)接受再分化治疗的33例RECIST进展的转移性碘难治性分化型甲状腺癌患者。
  • 所有患者接受基因组分析,并接受MEK、RET或ALK抑制剂单药或BRAF-MEK联合抑制剂治疗4周。
  • 在第3周,转移灶放射性碘亲和力增加的患者接受高剂量131I治疗。

主要发现

  • 33例患者中57.6%在再分化治疗后恢复放射性碘摄取(再分化亚组)。
  • 甲状腺乳头状癌再分化率为42.1%(8/19),浸润性包裹性滤泡变异型甲状腺乳头状癌为100%(4/4),滤泡性甲状腺癌为100%(7/7)。
  • RAS突变肿瘤全部再分化(11/11),而BRAF突变疾病再分化率为38.9%(7/18)(6例甲状腺乳头状癌和1例浸润性包裹性滤泡变异型甲状腺乳头状癌)。
  • 再分化亚组76.5%(13/17)和未再分化亚组66.7%(8/12)达到最佳总体RECIST缓解为疾病稳定(SD)或非完全缓解/非进展性疾病。
  • 两亚组在仅用药3周时肿瘤缩小中位均为12%;再分化亚组在高剂量131I治疗后6个月肿瘤额外缩小中位20%。

关键数值与推荐

  • 33例患者中57.6%恢复放射性碘摄取。
  • 甲状腺乳头状癌再分化率42.1%(8/19),浸润性包裹性滤泡变异型甲状腺乳头状癌100%(4/4),滤泡性甲状腺癌100%(7/7)。
  • RAS突变肿瘤再分化率100%(11/11),BRAF突变疾病再分化率38.9%(7/18)。
  • 再分化亚组76.5%(13/17)和未再分化亚组66.7%(8/12)达到最佳总体RECIST缓解为疾病稳定或非完全缓解/非进展性疾病。
  • 两亚组仅用药3周时肿瘤缩小中位均为12%;再分化亚组高剂量131I治疗后6个月肿瘤额外缩小中位20%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Redifferentiation therapy (RDT) can restore radioactive iodine (RAI) uptake in differentiated thyroid cancer (DTC) cells to enable salvage 131I therapy for previously RAI refractory (RAIR) disease. This study evaluated the clinical outcomes of patients who underwent RDT and identified clinicopathologic characteristics predictive of RAI restoration following RDT. Methods: This is a retrospective case series of 33 patients with response evaluation criteria in solid tumors (RECIST)-progressive metastatic RAIR-DTC who underwent RDT between 2017 and 2022 at the Mayo Clinic (Rochester, MN). All patients underwent genomic profiling and received MEK, RET or ALK inhibitors alone, or combination BRAF-MEK inhibitors for 4 weeks. At week 3, those with increased RAI avidity in metastatic foci received high-dose 131I therapy. Baseline and clinicopathologic outcomes were comprehensively reviewed. Results: Of the 33 patients, 57.6% had restored RAI uptake following RDT (Redifferentiated subgroup). 42.1% (8/19) with papillary thyroid cancers (PTC), 100% (4/4) with invasive encapsulated follicular variant PTCs (IEFV-PTCs), and 100% (7/7) with follicular thyroid cancers (FTC) redifferentiated. All (11/11) RAS mutant tumors redifferentiated compared with 38.9% (7/18) with BRAF mutant disease (6 PTC and 1 IEFV-PTC). 76.5% (13/17) of redifferentiated and 66.7% (8/12) of non-redifferentiated patients achieved a best overall RECIST response of stable disease (SD) or non-complete response/non-progressive disease. Both subgroups had a median 12% tumor shrinkage at 3 weeks on drug(s) alone. The redifferentiated subgroup, following high-dose 131I therapy, achieved an additional median 20% tumor reduction at 6 months after RDT. There were no statistically significant differences between both groups in progression free survival (PFS), time to initiation of systemic therapy, and time to any additional therapy. Of the entire cohort, 6.1% (2/33) experienced histologic transformation to anaplastic thyroid cancer, 15.1% (5/33) died, and all had redifferentiated following RDT and received 131I therapy. Conclusion: RDT has the potential to restore RAI avidity and induce RECIST responses following 131I therapy in select patients with RAIR-DTC, particularly those with RAS-driven "follicular" phenotypes. In patients with PTC, none of the evaluated clinical outcomes differed statistically between the redifferentiated and non-redifferentiated subgroups. Further studies are needed to better characterize the long-term survival and/or safety outcomes of high-dose RAI following RDT, particularly whether it could be associated with histologic anaplastic transformation.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Toro-Tobon D, Morris JC, Hilger C, et al. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers. Thyroid. 2023. PMID: 37917101. doi:10.1089/thy.2023.0456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。